NKTR) Makes Top Gainer List on News of REZOLVE-AD study

The stock makes the Nasdaq top percentage gainers list on news,
currently trading at $53.05  up 15.98  gaining 43.11%,
with a day’s high of $55.43.

Nektar Therapeutics today announced positive results from the
36-week blinded maintenance period of the 52-week REZOLVE-AD study
of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in
patients with moderate-to-severe atopic dermatitis (AD).

The global REZOLVE-AD Phase 2b study enrolled 393 patients with
moderate-to-severe atopic dermatitis. Patients were randomized
(3:3:3:2) to receive subcutaneous treatment with three doses of
rezpegaldesleukin or placebo for a 16-week induction period.
Following a 16-week induction period, rezpegaldesleukin-treated
patients who achieved Eczema Area Severity Index (EASI) percent
score reductions of at least 50 were re-randomized (1:1) to continue
at the same induction dose given monthly (Q4W) or quarterly (Q12W)
through week 52 in a blinded 36-week maintenance period. Patients
that did not achieve an EASI-50 during the 16-week induction period
entered into a treatment escape arm for up to 36 weeks.

Rezpegaldesleukin Demonstrated Long-Term Durability and Continued AD
Disease Symptom Improvement in Maintenance

Durability of Treatment Effect: Q4W and Q12W dosing regimens
resulted in sustained disease control for EASI-75, EASI-90,
validated Investigator Global Assessment of Atopic Dermatitis
(vIGA-AD) response, and Itch Numerical Rating Scale (NRS) response,
with the 24 µg/kg Q4W and Q12W regimens showing the highest
maintenance of response at week 52.

New and Deepening of Response Over Time: A meaningful proportion of
patients achieved new EASI-75, EASI-90, Itch NRS and vIGA-AD 0/1
responses at Week 52, supporting increased disease control with
prolonged therapy and less frequent dosing.

Meaningful Conversions to EASI-100: In maintenance, a 2 to 5-fold
increase in percentage of patients who achieved EASI-100 was
observed in the 24 µg/kg Q4W and Q12W dosing regimens. Among
all re-randomized patients from week 16 to week 52, Q4W maintenance
dosing increased EASI-100 response from 4% to 22% and Q12W dosing
increased EASI-100 response from 9% to 18%. Among re-randomized
patients who had an EASI-75 or vIGA-AD response at maintenance
baseline, Q4W dosing increased EASI-100 response from 6% to 30% and
Q12W dosing increased EASI-100 response from 14% to 27%.

“These data show that rezpegaldesleukin, as a broad-based Treg
agonist, is emerging as one of the most important mechanisms in
development to treat atopic dermatitis,” said Jonathan Silverberg,
MD, PhD, MPH, Professor of Dermatology at The George Washington
University School of Medicine and Health Sciences in Washington,
DC. “With both monthly and quarterly maintenance dosing, new and
sustained responses were observed across the key endpoints of
EASI-75, vIGA-0/1 and itch and with a large proportion of patients
achieving complete clearance with EASI-100.”

Full news 

https://ca.finance.yahoo.com/news/rezolve-ad-maintenance-data-atopic-120000860.html